Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering.

Journal for immunotherapy of cancer（2023）

引用 1|浏览1

暂无评分

摘要

These findings demonstrate that UB-VV100 generates functional CAR T cells in vivo, which could expand patient access to CAR T technology in both hematological and solid tumors without the need for ex vivo cell manufacturing.

查看译文

关键词

Cell Engineering,Drug Evaluation, Preclinical,Immunotherapy,Receptors, Chimeric Antigen,Translational Medical Research

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要